Whole-cell vaccines: A failure or a success waiting to happen?

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 14-20

  Copier, John ^a   Dalgleish, Angus ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic vaccine; Autologous vaccine; Cancer immunotherapy; Cancer vaccine; Immunomodulation; Immunosuppression

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BELAGENPUMATUCEL L; BIOLOGICAL MARKER; CANCER VACCINE; CANVAXIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENILEUKIN DIFTITOX; DOCETAXEL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOTOXIN LMB2; IPILIMUMAB; LENALIDOMIDE; MELACINE; ONYVAX P; PREDNISOLONE; PROVENGE; SUNITINIB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; WHOLE CELL VACCINE;

ADJUVANT THERAPY; ADVANCED CANCER; BIRD DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; OVARY CANCER; PROSTATE CANCER; RECTUM CANCER; RECTUM CARCINOMA; REVIEW; TREATMENT FAILURE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; WHOLE CELL VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INDUSTRY; HUMANS; NEOPLASMS;

EID: 76749149954     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 115(16):3670-3679.
2. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19):3089-3094.
3. Dendreon Corp: Dendreon submits clinical and non-clinical sections of rolling BLA to FDA for PROVENGE to treat advanced prostate cancer patients. Press Release (2006): August 24.
4. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J et al: Improving the efficacy of cancer immunotherapy. Eur J Cancer (2009) 45(8):1424-1431.
5. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599.
6. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM: Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits. Vaccine (2005) 23(17-18):2379-2387.
7. Dalgleish A, Pandha H: Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv Cancer Res (2007) 96:175-190.
8. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res (2004) 64(24):9209-9216.
9. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT et al: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 8(5):393-406.
10. Hanna MG Jr, Peters LC: Immunotherapy of established micrometastases with Bacillus Calmette-Guerin tumor cell vaccine. Cancer Res (1978) 38(1):204-209.
11. Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res (1979) 39(4):1353-1360.
12. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG: Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine. Melanoma Res (1996) 6(4):299-306.
13. Berger M, Kreutz FT, Horst JL, Baldi AC, Koff WJ: Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer. J Pharm Pharm Sci (2007) 10(2):144-152.
14. Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, O'Donnell D, Pandha HS, Selby PJ, Banks RE, Merrick AE et al: The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int (2009) 103(6):740-746.
15. Copier J, Ward S, Dalgleish A: Cell based cancer vaccines: Regulatory and commercial development. Vaccine (2007) 25(Suppl 2):B35-B46.
16. Hsueh EC, Morton DL: Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol (2003) 13(6):401-407.
17. Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS: Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. BJU Int (2002) 89(1):19-26.
18. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A: Lessons from randomized phase III studies with active cancer immunotherapies - Outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 25(Suppl 2):B97-B109.
19. Cell Genesys Inc: Cell Genesys announces termination of VITAL-1 phase III clinical trial of GVAX immunotherapy for prostate cancer based on outcome of futility analysis and reports preliminary analysis of VITAL-2 trial results. Press Release (2008): October 16.
20. Cell Genesys Inc: Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer. Press Release (2008): August 27.
21. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H: Delayed disease progression after allogeneic cell vaccination in hormoneresistant prostate cancer and correlation with immunologic variables. Clin Cancer Res (2005) 11(12):4469-4478.
22. Simons JW, Sacks N: Granulocyte-macrophage colonystimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol (2006) 24(5):419-424.
23. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M et al: Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 13(13):3883-3891.
24. GVAX Immunotherapy for Prostate Cancer: Cell Genesys Inc, San Francisco, CA, USA (2009). www.cellgenesys.com/view.cfm/20/ GVAX-Immunotherapy-for- Prostate-Cancer
25. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol (2009) 182(8):4499-4506.
26. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 113(5):975-984.
27. Copier J, Dalgleish A: Overview of tumor cell-based vaccines. Int Rev Immunol (2006) 25(5-6):297-319.
28. Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH et al: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA (2009) 106(37):15825-15830.
29. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother (2005) 54(6):587-598.
30. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmuller E, Buchcik R, Nagel M, Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res (1996) 2(1):21-28.
31. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial. Cancer Immunol Immunother (2009) 58(1):61-69.
32. Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V: Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol (2008) 33(4):823-832.
33. Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, Dalgleish A: T-regulatory cell modulation: The future of cancer immunotherapy? Br J Cancer (2009) 100(11):1697-1703.
34. Quezada SA, Peggs KS, Curran MA, Allison JP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 116(7):1935-1945.
35. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 23(25):6043-6053.
36. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA (2008) 105(8):3005-3010.
37. Tzai TS, Shiau AL, Liu LL, Wu CL: Immunization with TGF antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumorbearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res (2000) 20(3A):1557-1562.
38. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E et al: Phase II study of belagenpumatucel-L, a transforming growth factor 2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 24(29):4721-4730.
39. Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H: Phase II trial of belagenpumatucel-L, a TGF-2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther (2009) 16(8): 620-624.
40. NovaRx Corp: NovaRx initiates pivotal phase III clinical trial in lung cancer patients. Press Release (2008): August 21.
41. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 21(2):233-240.
42. Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A et al: Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma. Hum Gene Ther (2009):doi:10.1089/hum.2008. 192.
43. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G: Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 125(6):1372-1379.
44. Brill TH, Kubler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B: Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - A phase I clinical trial. J Gene Med (2007) 9(7):547-560.
45. Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A et al: Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother (2008) 31(1): 72-80.
46. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ: Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol (2008) 180(5):2011-2017; discussion 2017-2018.
47. Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS: Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res (2008) 14(12):3896-3905.
48. Cheever MA: Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 222:357-368.
49. Gulley JL, Madan RA, Arlen PM: Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 25(Suppl 2):B89-B96.
50. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 11(18): 6713-6721.
51. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 34(2):336-344.
52. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P et al: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2009) 58(7):1033-1045.
53. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 14(20):6674-6682.